Tango Therapeutics, a Cambridge, MA-based new cancer therapeutics company, raised $55m in Series A funding.
Third Rock Ventures was the founding backer of the new company.
Led by Barbara Weber, M.D., interim Chief Executive Officer and a Venture Partner at Third Rock Ventures, Tango Therapeutics aims to discover and develop novel medicines designed to target cancer vulnerabilities beyond mutated oncogenes to deliver new therapies for patients via a product engine that leverages advances in DNA sequencing and CRISPR-based target discovery.
The company is focused on three areas of drug development, including:
– Loss of tumor suppressor gene function,
– Multiple oncogenic drivers, and
– Immune evasion.
Company leaders include:
Barbara Weber, M.D., interim Chief Executive Officer;
Cary Pfeffer, M.D., interim Chief Business Officer;
Daniella Beckman, C.P.A., Chief Financial Officer;
Alan Huang, Ph.D., Senior Vice President, Head of Biology;
John Maxwell, Ph.D., Vice President, Head of Chemistry; and
Janid Ali, Ph.D., Vice President, Head of Biochemistry.
The founders are:
– Alan Ashworth, Ph.D., FRS, President of the University of California San Francisco Helen Diller Family Comprehensive Cancer Center;
– José Baselga, M.D., Ph.D., Physician-in-Chief at Memorial Sloan Kettering Cancer Center;
– Levi Garraway, M.D., Ph.D., Senior Vice President of Global Oncology at Eli Lilly and Company;
– William Kaelin, M.D., Professor in the Department of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School and a Howard Hughes Medical Institute Investigator;
– Timothy K. Lu, M.D., Ph.D., Associate Professor of Biological Engineering, Electrical Engineering and Computer Science at the Massachusetts Institute of Technology; and
– Antoni Ribas, M.D., Ph.D., Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles.